Not only is IL‐17 involved in alcoholic fatty liver disease, but has also been demonstrated to promote nonalcoholic fatty liver and nonalcoholic steatohepatitis, thus indicating that IL‐17 may contribute to MAFLD progression (Harley et al., 2014). Here, IL17A is linked to non-alcoholic fatty liver.